LAUSR

Introduction: Squamous cell carcinoma (SCC) accounts for 20-30% of lung cancer cases but new treatment options are limited. Retrospective subgroup analyses showed nab-paclitaxel (nab-P) plus carboplatin produced a significantly higher overall response rate (41%) than solvent-based paclitaxel plus carboplatin in patients with SCC. However, the safety and efficacy of combination chemotherapy of nab-p and carboplatin has not yet been established for patients with concurrent SCC and interstitial lung disease (ILD). Objectives: The aim of study was to assess the safety and efficacy profiles of the nab-P and carboplatin in patients with SCC and ILD. Methods Eight patients with inoperable stage SCC and preexisting ILD were treated with nab-P plus carboplatin in a first line setting between Jun 2013 and December 2016. One of the eight was a woman and the median age was 77 (range=72-80) years. Their clinical outcomes including chemotherapy-associated acute exacerbation of ILD were retrospectively investigated. Results: The overall response rate was 50 %, the median progression-free survival time was 4.9 months, and the median overall survival time was 7.2 months. No patients experienced chemotherapy-related exacerbation of ILD in the first line treatment with nab-P and carboplatin. However, ILD worsened in two of four patients who received second line chemotherapy. Conclusion: Nab-p plus carboplatin combination chemotherapy could be a feasible treatment option for patients with inoperable SCC with ILD. To confirm the efficacy and safety of this regimen, a large-scale prospective study is needed.